Company intelligence / Profile preview

Connext

Seongnam-si, Gyeonggi-do, South Koreaconextconference.africa ↗

Ownership: Private
Development stage: Other

Overview

Connext is a clinical-stage biotech company developing first-in-class biological therapeutics. Its lead program CNT201, a recombinant collagenase, completed the dose escalation part of its US FDA-cleared Phase I/II trial for Dupuytren's contracture with top-line data expected in the first half of 2026. CNT101, a recombinant TLR5 agonist, has IND clearance and is entering clinical trials for acute graft-versus-host disease. The company also develops therapies targeting oral mucositis and cancer immunotherapy as well as regenerative medicine applications.

Therapeutic areas: Men's HealthOncologyImmunologyHematologyDermatologyRheumatologyGastroenterology
Modalities: Recombinant proteinBiologicEnzyme (for collagenase programs)
Industry: Biotech

Beyond the preview

Go deeper on Connext.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Connext.

Explore the full profile